No connection

Search Results

GRAL vs JNJ

GRAL
GRAIL, Inc.
BEARISH
Price
$45.63
Market Cap
$1.87B
Sector
Healthcare
AI Confidence
85%
JNJ
Johnson & Johnson
NEUTRAL
Price
$244.85
Market Cap
$590.06B
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
GRAL
--
JNJ
22.22
Forward P/E
GRAL
-5.04
JNJ
19.48
P/B Ratio
GRAL
0.71
JNJ
7.23
P/S Ratio
GRAL
12.72
JNJ
6.26
EV/EBITDA
GRAL
-2.71
JNJ
18.27

Profitability

Gross Margin
GRAL
48.46%
JNJ
68.08%
Operating Margin
GRAL
-285.37%
JNJ
23.97%
Profit Margin
GRAL
-277.46%
JNJ
28.46%
ROE
GRAL
-16.07%
JNJ
35.03%
ROA
GRAL
-11.31%
JNJ
8.68%

Growth

Revenue Growth
GRAL
14.0%
JNJ
9.1%
Earnings Growth
GRAL
--
JNJ
48.6%

Financial Health

Debt/Equity
GRAL
0.02
JNJ
0.6
Current Ratio
GRAL
11.97
JNJ
1.03
Quick Ratio
GRAL
11.58
JNJ
0.69

Dividends

Dividend Yield
GRAL
--
JNJ
2.13%
Payout Ratio
GRAL
0.0%
JNJ
46.6%

AI Verdict

GRAL BEARISH

GRAL exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating critical operational instability. While the company maintains an exceptionally high current ratio (11.97) and low debt, these are offset by catastrophic profit margins (-277.46%) and a bearish technical trend. Despite consistent earnings beats relative to low expectations and a 'Buy' analyst consensus, heavy insider selling ($95.49M) suggests a lack of confidence from leadership.

Strengths
Extremely high liquidity with a current ratio of 11.97
Very low leverage (Debt/Equity of 0.02)
Positive gross margins (48.46%) indicating product viability
Risks
Critical operational health (Piotroski F-Score 1/9)
Severe negative profitability and operating margins
Aggressive insider selling with zero buy transactions
JNJ NEUTRAL

JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.

Strengths
Strong profitability (28.5% margin)
Strong ROE of 35.0%
Risks
Premium vs Graham Number ($91.63)
Weak financial trend (Piotroski F-Score: 3/9)

Compare Another Pair

GRAL vs JNJ: Head-to-Head Comparison

This page compares GRAIL, Inc. (GRAL) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile